

SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

Current report filing

Filing Date: **2013-06-10** | Period of Report: **2013-06-05**  
SEC Accession No. [0001171843-13-002444](#)

([HTML Version](#) on [secdatabase.com](#))

FILER

**PAIN THERAPEUTICS INC**

CIK: **1069530** | IRS No.: **911911336** | State of Incorporation: **DE** | Fiscal Year End: **1231**  
Type: **8-K** | Act: **34** | File No.: **000-29959** | Film No.: **13903741**  
SIC: **2834** Pharmaceutical preparations

Mailing Address

7801 N CAPITAL OF TEXAS  
HIGHWAY  
SUITE 260  
AUSTIN TX 78731

Business Address

7801 N CAPITAL OF TEXAS  
HIGHWAY  
SUITE 260  
AUSTIN TX 78731  
512-501-2444

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 10, 2013 (June 5, 2013)

**Pain Therapeutics, Inc.**

(Exact name of registrant as specified in its charter)

**DELAWARE**  
(State or other jurisdiction  
of incorporation)

**000-29959**  
(Commission File Number)

**91-1911336**  
(IRS Employer  
Identification No.)

**7801 N. Capital of Texas Highway, Suite 260**  
**Austin, Texas 78731**  
(Address of principal executive offices, including zip code)

**512-501-2444**  
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On June 5, 2013, the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Pain Therapeutics, Inc. (the “Company”) approved changes in compensation for the Company’s named executive officers (as defined in Item 402(a)(3) of Regulation S-K promulgated by the Securities and Exchange Commission) with respect to the officers’ and the Company’s performance from mid-2012 to mid-2013.

The base salary for Remi Barbier, President and Chief Executive Officer, was increased to \$725,000 per year from \$700,000 per year. The base salary for Nadav Friedmann, Ph.D., M.D., Chief Medical and Operating Officer was increased to \$275,000 per year from \$250,000. The base salary for Peter S. Roddy, Vice President and Chief Financial Officer was increased to \$330,000 from \$300,000 per year. The base salary for Grant L. Schoenhard, Ph.D., Chief Scientific Officer was increased to \$275,000 from \$250,000 per year.

Bonus payments for the named executive officers were:

<u>Name</u>	<u>Title</u>	<u>Bonus</u>
Remi Barbier	President and Chief Executive Officer	\$ 300,000
Nadav Friedmann, Ph.D., M.D.	Chief Medical and Operating Officer	\$ 110,000
Peter S. Roddy	Vice President and Chief Financial Officer	\$ 50,000
Grant L. Schoenhard, Ph.D.	Chief Scientific Officer	\$ 60,000

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Pain Therapeutics, Inc.

Dated: June 10, 2013

By: /s/ Peter S. Roddy

Peter S. Roddy

*Vice President and Chief Financial Officer*